



NDA 20802/S-033

SUPPLEMENT APPROVAL

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
Attention: Rita D. Patel, RAC
Regulatory Affairs Manager
184 Liberty Corner Road
Warren, NJ 07059

Dear Ms. Patel:

Please refer to your Supplemental New Drug Application (sNDA) dated and received March 29, 2019, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Excedrin® Migraine (acetaminophen 250 mg/aspirin 250 mg/caffeine 65 mg) tablet.

This supplemental new drug application provides for labeling for the 30-ct (24+6) capsule-shaped tablet (caplet) product. In addition, this submission requests removal of the 10-ct capsule-shaped tablet (caplet) product from the NDA.

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling, as soon as they are available, but no more than 30 days after they are printed. The final printed labeling must be identical to the labeling below and must be in the “Drug Facts” format (21 CFR 201.66), where applicable

Submitted Labeling	Submission Date
30-ct (24+6) tablet (capsule-shaped) outer container (carton)	March 29, 2019
30-ct (24+6) tablet (capsule-shaped) immediate container (bottle)	March 29, 2019

The final printed labeling should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2017, Revision 4)*. For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 20802/S-033.**” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Tinya Sensie, Regulatory Project Manager, at (240) 402-4230.

Sincerely,

{See appended electronic signature page}

Karen Murry Mahoney, MD, FACE
Deputy Director
Division of Nonprescription Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURE(S):
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

KAREN M MAHONEY
04/15/2019 12:37:20 PM